Document Detail


Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.
MedLine Citation:
PMID:  22955957     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Botulinum toxin type A (BTX-A) represents the gold standard therapy for focal spasticity after stroke, with low prevalence of complications, reversibility, and efficacy in reducing spastic hypertonia. Current guidelines suggest the employment of a dosage up to 600 units (U) of BTX-A to treat spasticity after stroke, to avoid important adverse effects and the development of antibodies against the neurotoxin. In recent years, NT 201, a new BTX-A free of complexing proteins, has been used for treating several movement disorders, showing safety and efficacy in upper limb spasticity. In a prospective, non-randomized, open-label study, we studied the efficacy and safety of higher doses of BTX-A NT 201 (up to 840 U) in 25 consecutive patients with upper and lower limb spasticity after stroke, evaluated at 30 and 90 days after injections. Before and after the treatment, the grade of spasticity, the disability, and spasticity-related pain were extensively measured. After 30 days of follow-up, a great reduction of spasticity and pain with improvement of disability was observed. The effects were still present at 90 days of follow-up. No major adverse events were observed. Higher doses of BTX-A NT 201 appeared to be safe and efficacious in patients with upper and lower limb spasticity after stroke. However, further investigations are needed to determine its reproducibility in larger case series or randomized clinical trials and to observe the absence of antibodies against the neurotoxin also after repeated injections.
Authors:
Andrea Santamato; Francesco Panza; Maurizio Ranieri; Vincenza Frisardi; Maria Francesca Micello; Serena Filoni; Francesca Fortunato; Domenico Intiso; Mario Basciani; Giancarlo Logroscino; Pietro Fiore
Related Documents :
24615407 - The short- and medium-term effectiveness of ct-guided selective cervical nerve root inj...
12663167 - Volcanic emissions of mercury to the atmosphere: global and regional inventories.
25075767 - How does rectus femoris fibrosis affect gait?
22941747 - Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.
11854757 - How an audit of epidural patients in a community hospital setting resulted in the devel...
10430687 - Peritoneal response to a septic challenge. comparison between open laparotomy, pneumope...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-7
Journal Detail:
Title:  Journal of neural transmission (Vienna, Austria : 1996)     Volume:  -     ISSN:  1435-1463     ISO Abbreviation:  J Neural Transm     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9702341     Medline TA:  J Neural Transm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Physical Medicine and Rehabilitation, "OORR Hospital", University of Foggia, Viale Pinto, 71100, Foggia, Italy, a.santamato@unifg.it.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The positive influence of boron-doped graphene for its supported Au clusters: enhancement of SERS an...
Next Document:  Appearance of neural stem cells around the damaged area following traumatic brain injury in aged rat...